Efremov E A, Kasatonova E V, Mel'nik Ya I, Nikushina A A
Department of Andrology and Human Reproduction, N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology branch of NMRRC of Minzdrav of Russia, Moscow, Russia.
Urologiia. 2018 May(2):108-113.
Erectile dysfunction (ED) has a significant negative impact on the quality of life of the patients and their partners. The sequence and regimens of ED therapy have become quite evident since the advent of phosphodiesterase type 5 inhibitors (PDE-5). However, there have been continued basic research of the efficacy and safety of these agents and studies aimed at new therapeutic goals. In recent years, the attention of researchers has shifted into a wider range of issues related to the personalized PDE-5 therapy, including sexual satisfaction, psychosocial variables (e.g., confidence, self-esteem, quality of relationships) and other potentially related factors. In particular, there are more and more new data on male sexual dysfunction. This review focuses on the relationship between erectile dysfunction and concomitant conditions: depressive symptoms, libido and sexual satisfaction disorders, ejaculation and orgasm abnormalities. The authors outline the possibilities and potential benefits of PDE-5 for patients with comorbid sexual dysfunction and depression with a special focus on tadalafil.
勃起功能障碍（ED）对患者及其伴侣的生活质量有重大负面影响。自5型磷酸二酯酶抑制剂（PDE-5）问世以来，ED治疗的顺序和方案已相当明确。然而，针对这些药物的疗效和安全性仍在持续进行基础研究，并且有旨在实现新治疗目标的研究。近年来，研究人员的注意力已转向与个性化PDE-5治疗相关的更广泛问题，包括性满意度、心理社会变量（如自信心、自尊、人际关系质量）以及其他潜在相关因素。特别是，关于男性性功能障碍的新数据越来越多。本综述重点关注勃起功能障碍与伴随病症之间的关系：抑郁症状、性欲和性满意度障碍、射精和性高潮异常。作者概述了PDE-5对合并性功能障碍和抑郁症患者的可能性和潜在益处，特别关注他达拉非。
